Oppenheimer & Co’s Catalyst Pharmaceutical CPRX Stock Holding History

Oppenheimer & Co’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.69M	Sell	68,116 -38,862	-36%	-$926K	0.02%	657
2025 Q4	$2.5M	Buy	106,978 +15,001	+16%	+$334K	0.04%	480
2025 Q3	$1.81M	Sell	91,977 -11,293	-11%	-$232K	0.02%	642
2025 Q2	$2.24M	Buy	103,270 +4,524	+5%	+$107K	0.03%	537
2025 Q1	$2.39M	Sell	98,746 -5,741	-5%	-$129K	0.04%	493
2024 Q4	$2.18M	Buy	104,487 +23,078	+28%	+$496K	0.03%	513
2024 Q3	$1.62M	Sell	81,409 -5,314	-6%	-$98.5K	0.02%	616
2024 Q2	$1.34M	Buy	86,723 +36,192	+72%	+$563K	0.02%	660
2024 Q1	$805K	Buy	+50,531	New	+$761K	0.01%	818

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Oppenheimer & Co's CPRX Position: Q1 2026 in Review

Oppenheimer & Co reduced its Catalyst Pharmaceutical (CPRX) stake by 36% in Q1 2026, selling an estimated $926K and leaving 68,116 shares worth $1.69M. The position accounts for 0.02% of the portfolio, ranked #657.

Oppenheimer & Co first reported a position in CPRX in Q1 2024 and has held it in 9 quarters since. The position peaked at $2.5M in Q4 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

Oppenheimer & Co held 68,116 shares of Catalyst Pharmaceutical worth $1.69M as of Q1 2026.
Oppenheimer & Co sold 38,862 Catalyst Pharmaceutical shares in Q1 2026, an estimated $926K.
Catalyst Pharmaceutical made up 0.02% of Oppenheimer & Co's portfolio in Q1 2026, its #657 holding.
Oppenheimer & Co first reported a position in Catalyst Pharmaceutical in Q1 2024 and has held it in 9 quarters since.
Oppenheimer & Co's Catalyst Pharmaceutical position peaked at $2.5M in Q4 2025.
380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Oppenheimer & Co's 13F filing for Q1 2026, filed 24 Apr 2026.